Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...

Merck Foundation in partnership with African First Ladies and Ministries of Health and Medical Societies provided out of total 2080 Scholarships, 830 Scholarships of one-year Post-Graduate Diploma and ...

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

In a report released on October 16, Oliver Reinberg from Kepler Capital maintained a Buy rating on Draegerwerk AG & Co. KGaA (0K5E ...